Meta Pixel
Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

News and Announcements

World’s First Wearable Ring for Blood Sugar Measurement | Clinical Study Successful

  • Published August 18, 2021 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Opuz is developing a world-first wearable ring that monitors blood glucose levels. Unlike current blood sugar measurement options, Opuz is non-invasive and pain-free.

We recently concluded a successful clinical study demonstrating accuracy versus a market-leading product and intend to publish the results in the Journal of Diabetes Science and Technology.

Opuz is raising $2M to complete product development and is aiming to launch its first sales in mid-2022.

Andrew Just, CEO, Opuz

Register Interest

Executive Summary

Leveraging design, innovation, and the latest technology to disrupt traditional monitoring models, Opuz is developing a truly non-invasive blood glucose monitor that is easy to use and affordable. The company’s vision is to enable easy self-monitoring of vital health metrics, and its first metric of focus is blood glucose.

Opuz’s approach is to couple novel sensor technology (bioimpedance) with cloud-based AI to comfortably and continuously monitor blood sugar levels.

The Opuz ring requires no action from the user and negates the need for needles, sticky skin patches, and finger pricks.  The company is poised to disrupt a global $13B market and launch the product in 2022.

Investment Highlights

Growth of sector

  • The value of the global market for self-monitoring of blood glucose is $13B. The market keeps growing as diabetes continues to spread around the world.  It is a massive market with substantial adjacent markets that Opuz can tap into through its technology approach.
  • Opuz will be launching as a wellness product in 2022, accelerating the path to market and aiming to tap into the unmet need of easy and pain-free monitoring quickly. As a general consumer wellness product, it provides a straightforward and streamlined path to market.

Competitive advantages

  • Opuz is positioned to be easier, faster, and more affordable than current products.
  • The product has less than half the annual cost of the market-leading CGM. When compared with finger-prick testing, it is the more affordable and pain-free option.
  • The company’s business model of wearable + SaaS provides recurring revenue on an app platform that can expand services over time, with the capability to access adjacent markets such as services and therapies.

Experienced management and advisory board

  • The company has a mix of experience focused on go-to-market needs, supported by expert clinician knowledge. Omnichannel B2C experience, a leading social media influencer in this space, global commercial experience in related sales, and clinician specialists in endocrinology all contribute to the company’s advisory pool of knowledge.

Investment Offering

Opuz is raising $2M on a pre-money enterprise value of $20M to complete product development and initiate the commercial launch of first sales.

Register Interest

Capital Insights
Cosmo Innovations Founder Eyes Global Rollout of SkinGate, IPO by 2027

Dr. Mathew Jafarzadeh, founder of Cosmo Innovations, is set to revolutionize the $65 billion home beauty tech market with SkinGate, a patented skincare infusion device. Following his presentation at Emergence 2025, he revealed plans for a global rollout, aiming for a 2027 IPO on NASDAQ or the Hong Kong Exchange. Discover how SkinGate, backed by 110+ patents, seeks to attract “smart capital” and redefine skincare delivery.

Company Updates
Stop Leaving Millions on the Table: The Investor Secret You’re Missing!

In an Australian business landscape increasingly defined by volatility and intense competition for capital, the art of robust stakeholder relations has evolved beyond a mere governance checkbox. For founders, boards, and executive teams, the ability to genuinely inform and engage investors isn’t just about meeting disclosure requirements; it’s a strategic imperative that directly impacts capital […]

Capital Insights
Ecosystems Over Exit: Callum Laing on Disrupting Small Business M&A

At Emergence Singapore, Callum Laing of Veblen Director Program presented a bold new vision for small business M&A: “Ecosystems Over Exit.” He shared how his Unity Group takes cash-generating businesses public, focusing on growth over immediate founder exit. Discover his unique approach, how interconnected ecosystems drive massive deal flow, and a three-step framework for any business to amplify reach and capital raising.

Join over 45,000+ sophisticated investors

Join Now